Author

I. T. Shah

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 2 Biochemistry· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 3 Approach:experimental assay· 3 Organism:mouse· 3 Organism:human· 2 Organism:bacteria (other)· 1 Research Focus:protein folding & dynamics· 1 Assay:proteomics· 1 Approach:statistical model· 1

Frequent Co-Authors

A. R. Odom John· 3 shared C. S. Dowd· 3 shared R. L. Edwards· 3 shared C.-A. D. Burnham· 2 shared J. J. Miller· 2 shared J. M. Jez· 2 shared K. M. Heidel· 2 shared M. O. Mikati· 2 shared

Activity by Year

2020-2020 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 40 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersMicrobiology

A. R. Odom John

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Structure-guided microbial targeting of antistaphylococcal prodrugs

J. Miller, I. T. Shah, J. Hatten, Y. Barekatain, E. A. Mueller, A. M. Moustafa, R. L. Edwards, C. S. Dowd, P. J. Planet, F. L. Muller, J. M. Jez, A. R. Odom John

This study identifies microbial esterases in Staphylococcus aureus and determines their substrate specificities to guide the design of serum esterase-resistant antistaphylococcal prodrugs.

bioRxiv · Dec 15, 2020Biochemistry

Antimicrobial prodrug activation by the staphylococcal glyoxalase GloB

M. O. Mikati, J. J. Miller, D. M. Osbourn, N. Ghebremichael, I. T. Shah, C.-A. D. Burnham, K. M. Heidel, V. C. Yan, F. L. Mueller, C. S. Dowd, R. L. Edwards, A. R. Odom John

This study identifies GloB as a bacterial enzyme that activates carboxy ester prodrugs, suggesting its potential for developing targeted prodrug therapies against staphylococcal species.

ACS Infectious Diseases · Oct 29, 2020Peer-reviewedMicrobiology

Potent, specific MEPicides for treatment of zoonotic staphylococci

R. L. Edwards, I. Heueck, S. G. Lee, I. T. Shah, A. J. Jezewski, J. J. Miller, M. O. Mikati, X. Wang, R. C. Brothers, K. M. Heidel, C.-A. D. Burnham, S. Alvarez, S. A. Fritz, C. S. Dowd, J. M. Jez, A. R. Odom John

This paper identifies DXR as a druggable target for zoonotic staphylococci and develops potent prodrug inhibitors (MEPicides) that bypass transporter requirements.

PLOS Pathogens · Jun 4, 2020Peer-reviewedMicrobiology